Lysoway Therapeutics received $3.4 million to develop oral TMEM175 agonists targeting lysosomal function in Parkinson's disease. The approach addresses a genetically-linked mechanism of neurodegeneration by modulating how cells clear and recycle damaged proteins—a process that deteriorates with age and cellular stress.
Key Points
- TMEM175 agonists enhance lysosomal clearance in aging neurons
- Oral bioavailability enables non-invasive brain-targeted therapy
- Genetic evidence links lysosomal dysfunction to Parkinson's risk
Longevity Analysis
Lysosomal dysfunction is a hallmark of neurodegeneration and aging. As cells accumulate damaged proteins and lipids over time, the cellular recycling machinery falters—a cascade that accelerates cognitive decline and motor dysfunction. By targeting TMEM175 ion channels to restore lysosomal capacity, this approach addresses a root mechanism rather than symptom management. The focus on protein and lipid homeostasis under aging and stress conditions reflects the recognition that longevity depends on the body's ability to continuously clear cellular waste and maintain neuronal health across decades. An orally bioavailable small molecule that penetrates the brain represents a significant advancement over approaches requiring systemic administration or poor CNS penetration.
Original published by LT Wire.